Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
– Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST
SCHLIEREN (ZURICH), SWITZERLAND / ACCESSWIRE / March 8, 2024 / Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024. Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results.
To register for the video call, click here.
For further information, please contact:
| Kuros Biosciences AG Daniel Geiger Chief Financial Officer t: +41 44 733 47 47 e: daniel.geiger@kurosbio.com |
LifeSci Advisors Sandya von der Weid Investors t: +41 78 680 0538 e: svonderweid@lifesciadvisors.com |
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across three continents and in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit kurosbio.com.
SOURCE: Kuros Biosciences AG
View the original press release on accesswire.com
Related news for (CSBTF)
- Kuros Biosciences Reports First Half of 2024 Results
- Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
- Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
- Annual General Meeting of Kuros Biosciences Approves All Resolutions
- Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023